Use of elexacaftor plus tezacaftor plus ivacaftor in individuals with cystic fibrosis and at least one <i>F508del</i> allele: a systematic review and meta-analysis

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
Autores
TONON, Carolina Rodrigues
Citação
JORNAL BRASILEIRO DE PNEUMOLOGIA, v.49, n.6, article ID e20230187, 11p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To evaluate the effect of treatment with the combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators-elexacaftor+tezac aftor+ivacaftor (ETI)-on important clinical endpoints in individuals with cystic fibrosis. Methods: This was a systematic review and meta-analysis of randomized clinical trials that compared the use of ETI in individuals with CF and at least one F508del allele with that of placebo or with an active comparator such as other combinations of CFTR modulators, following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) recommendations and the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) methodology. We searched the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception to December 26th, 2022. The risk of bias was assessed using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We retrieved 54 studies in the primary search. Of these, 6 met the inclusion criteria and were analyzed (1,127 patients; 577 and 550 in the intervention and control groups, respectively). The meta-analysis revealed that the use of ETI increased FEV 1% [risk difference (RD), +10.47%; 95% CI, 6.88-14.06], reduced the number of acute pulmonary exacerbations (RD, -0.16; 95% CI, -0.28 to -0.04), and improved quality of life (RD, +14.93; 95% CI, 9.98-19.89) and BMI (RD, +1.07 kg/m(2); 95% CI, 0.90-1.25). Adverse events did not differ between groups (RD, -0.03; 95% CI, -0.08 to 0.01), and none of the studies reported deaths. Conclusions: Our findings demonstrate that ETI treatment substantially improves clinically significant, patientcentered outcomes.
Palavras-chave
Cystic fibrosis/therapy, Cystic fibrosis transmembrane conductance regulator, Membrane transport modulators
URI
https://observatorio.fm.usp.br/handle/OPI/58252
Referências
  1. Amaral MD, 2005, PEDIATR PULM, V39, P479, DOI 10.1002/ppul.20168
  2. [Anonymous], 2020, Review Manager (RevMan)
  3. Athanazio RA, 2023, J BRAS PNEUMOL, V49, DOI 10.36416/1806-3756/e20230040
  4. Bacalhau M, 2023, PHARMACEUTICALS-BASE, V16, DOI 10.3390/ph16030410
  5. Barry PJ, 2021, NEW ENGL J MED, V385, P815, DOI 10.1056/NEJMoa2100665
  6. Bell SC, 2020, LANCET RESP MED, V8, P65, DOI 10.1016/S2213-2600(19)30337-6
  7. Bell SC, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0887-6
  8. Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041
  9. Bower JK, 2023, J CYST FIBROS, V22, P730, DOI 10.1016/j.jcf.2023.03.002
  10. Burgel PR, 2021, AM J RESP CRIT CARE, V204, P64, DOI 10.1164/rccm.202011-4153OC
  11. Burgel PR, 2020, AM J RESP CRIT CARE, V201, P188, DOI 10.1164/rccm.201906-1227OC
  12. Capurro V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105262
  13. Davies JC, 2018, NEW ENGL J MED, V379, P1599, DOI 10.1056/NEJMoa1807119
  14. da Silva LVRF, 2021, J CYST FIBROS, V20, P473, DOI 10.1016/j.jcf.2020.08.007
  15. da Silva LVRF, 2021, PAEDIATR RESPIR REV, V38, P37, DOI 10.1016/j.prrv.2020.07.004
  16. FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003
  17. GDT G., 2020, GRADEPRO GDT GRADEPR
  18. Goralski JL, 2023, AM J RESP CRIT CARE, V208, P59, DOI 10.1164/rccm.202301-0084OC
  19. Goss CH, 2019, SEMIN RESP CRIT CARE, V40, P792, DOI 10.1055/s-0039-1697975
  20. Goss CH, 2018, AM J RESP CRIT CARE, V197, P768, DOI 10.1164/rccm.201707-1541OC
  21. Grasemann H, 2013, LANCET RESP MED, V1, P148, DOI 10.1016/S2213-2600(13)70026-2
  22. Greenawald L, 2018, PEDIATR PULM, V53, P157
  23. Habib AR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43652-2
  24. Heijerman HGM, 2019, LANCET, V394, P1940, DOI 10.1016/S0140-6736(19)32597-8
  25. Keating D, 2018, NEW ENGL J MED, V379, P1612, DOI 10.1056/NEJMoa1807120
  26. Mall MA, 2022, AM J RESP CRIT CARE, V206, P1361, DOI 10.1164/rccm.202202-0392OC
  27. Mall MA, 2020, AM J RESP CRIT CARE, V201, P1193, DOI 10.1164/rccm.201910-1943SO
  28. McColley SA, 2016, EXPERT OPIN DRUG SAF, V15, P709, DOI 10.1517/14740338.2016.1165666
  29. McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411
  30. Mendoza JL, 2012, CELL, V148, P164, DOI 10.1016/j.cell.2011.11.023
  31. Middleton PG, 2019, NEW ENGL J MED, V381, P1809, DOI 10.1056/NEJMoa1908639
  32. O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5
  33. Page MJ, 2022, REV PANAM SALUD PUBL, V46, DOI [10.1186/s13643-021-01626-4, 10.26633/RPSP.2022.112, 10.1371/journal.pmed.1003583, 10.1016/j.rec.2021.07.010, 10.1016/j.jclinepi.2021.03.001, 10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]
  34. Rabeh WM, 2012, CELL, V148, P150, DOI 10.1016/j.cell.2011.11.024
  35. Ramsey BW, 2011, NEW ENGL J MED, V365, P1663, DOI 10.1056/NEJMoa1105185
  36. Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104
  37. Ratjen F, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.10
  38. Rowe SM, 2014, AM J RESP CRIT CARE, V190, P175, DOI 10.1164/rccm.201404-0703OC
  39. Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749
  40. Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
  41. Sutharsan S, 2022, LANCET RESP MED, V10, P267, DOI 10.1016/S2213-2600(21)00454-9
  42. Wainwright CE, 2015, NEW ENGL J MED, V373, P220, DOI 10.1056/NEJMoa1409547
  43. Wang YZ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.863280
  44. Zampoli M, 2022, J CYST FIBROS, V21, pE215, DOI 10.1016/j.jcf.2022.03.006

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - LIM/36
Carregar mais